濮阳东方看男科很靠谱(濮阳东方医院治早泄评价很高) (今日更新中)

The City of Tucson rejected the resignation of Tucson Police Department Chief Chris Magnus Thursday.According to City Council member Steve Kozachik, City Manager Michael Ortega rejected the resignation. Magnus has helmed TPD since January 2016.Magnus offered his resignation at a Wednesday press conference in which TPD revealed video of the incident in which 27-year-old Carlos "Adrian" Ingram Lopez died in police custody April 21.TIMELINE: What happened after a man died while in TPD custodyMayor Regina Romero said Magnus has the support of her office, as well as the City Council.Here is Romero's statement: 620

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

The fine print of newly released federal guidelines for reopening schools raises serious questions about whether in-person classes should resume at a time when COVID-19 rages around much of the country.Last week, the Centers for Disease Control and Prevention (CDC), under pressure from the White House, released a position paper highlighting “the importance of reopening America’s schools this fall.”But separate guidelines issued for K-12 school administrators, which drew less public attention, are much more cautious.“It is important to consider community transmission risk as schools reopen,” those CDC guidelines state.“Computer simulations from Europe have suggested the school reopenings may further increase transmission risk in communities where transmission is already high.”Buried at the bottom of the new CDC recommendation to re-open schools is a HUGE caveat! #COVID19 poses a low risk to kids “at least in areas with low community transmission.” That’s not where much of the country stands right now. 4/ pic.twitter.com/0D5CPxhlIb— Phil Williams (@NC5PhilWilliams) July 25, 2020 The new CDC guidelines suggest, “If community transmission levels cannot be decreased, school closure is an important consideration.”“Plans for virtual learning should be in place in the event of a school closure.”In Tennessee, several public and private schools are preparing to reopen even as almost every county in the state is showing what the Department of Health considers to be unacceptable rates of transmission of the coronavirus.Last week, the American Academy of Pediatrics issued a dramatic clarification of its statement back in June that "all policy considerations for the coming school year should start with a goal of having students physically present in school.""This does not mean that we recommend that all schools open five days a week from the start of the school year," the academy’s Dr. Sean O'Leary told a congressional committee.“Many parts of the country are currently experiencing uncontrolled spread of COVID-19. While the AAP urges those areas to make in-person learning as the goal, we recognize that many jurisdictions will need to utilize distance learning strategies until cases decline."The vice chair of the academy's committee on infectious diseases, O'Leary told the subcommittee that, where there is uncontrolled community transmission, "it's inevitable that the virus is going to get into the schools, and schools are going to have to shut down."U.S. Surgeon General Jerome M. Adams also told CBS This Morning last week that a community's COVID-19 transmission rate is the single most important determinant of whether schools can safely reopen.School reopening advocates point to the emotional, psychological and educational importance of children being in the classroom – a position that the CDC guidelines reaffirm.“Schools provide safe and supportive environments, structure and routines for children, as well as other needed support services to children and families,” the CDC notes.Children are less likely to become ill when infected with the virus, and younger children are less likely to transmit the virus to others, the report adds.But a large-scale study out of South Korea recently reported that children ages 10-19 -- middle- and high-school ages -- can spread the virus as easily as adults.Also, in searching citations in the new CDC recommendation to re-open schools, it appears to completely leave out the large-scale South Korea study that found teens are likely to spread #COVID19 as readily as adults 5/ https://t.co/ABLPvpKQU5— Phil Williams (@NC5PhilWilliams) July 25, 2020 In addition, a new study – shared by the Tennessee Department of Health last week on Twitter – concluded that “young, previously healthy adults can take a long time to recover from COVID-19.” 3828

The Federal Aviation Administration (FAA) has cleared the Boeing 737 Max to return to the skies, The Associated Press reports.The plane has been grounded in the U.S. since March 2019 after it was involved in two deadly crashes just months after initial orders for the model had been fulfilled. The two crashes — one which occurred in Africa, the other in Asia — killed a combined 346 people.In Congressional hearings last September, Boeing officials say the plane's software included a fatal flaw that caused a nosedive in certain situations.In addition to the human cost of the software error, the Boeing 737 Max has proven to be malignant for Boeing's business. According to CNN, Boeing says the grounding of the 737 Max has resulted in billion in direct costs. Boeing's stock fell 100 points between March 2019 and January 2020 — a massive loss even before the COVID-19 pandemic dragged the entire market down with historic losses. "These 20 months they took to look at every possible issue with the aircraft is more than enough time to make it safe to go back in the air," said Kevin Kuhlmann, an Aviation and Aerospace Science Professor at Metro State University. "It's no small undertaking to go through and develop this training, put the pilots through the training and absorb the cost of the training."In October, American Airlines announced it would begin using the plane on certain routes in late December, pending FAA approval. The company says it will provide flexibility to passengers who do not want to fly on the plane.Other airlines like Southwest say they won't be putting the plane back in rotation until April. 1641

The Centers for Disease Control and Prevention is coming to Stark County, Ohio to investigate the area’s startling rate of teen suicides, according to the Ohio Department of Health.Federal health experts will spend two weeks here to figure out why a dozen Stark County teenagers have died by suicide since the end of summer.The CDC visit comes at the request of local and state health officials. According to the Canton Repository: 449

来源：资阳报